

**Brian O'Mahony, President**  
**Amanda Bok, CEO**  
European Haemophilia Consortium  
Rue de l'Industrie,10  
1000 Brussels  
Belgium

Friday, 16 June 2017

**Subject: Letter in Support of the Procurement of Affordable Replacement Therapies – Network of European Relevant Stakeholders (PARTNERS) Programme**

Dear Brian, dear Amanda,

On behalf of our Board of Directors, EURORDIS – Rare Diseases Europe is pleased to convey our full support of the Procurement of Affordable Replacement Therapies - Network of European Relevant Stakeholders (PARTNERS) programme.

We very much welcome the creation of such an innovative and much-needed programme towards addressing the needs of patients with haemophilia both inside and outside of the European Union in accessing adequate supply of clotting factor concentrates.

We also commend the programme for prioritising the involvement of clinicians and patient representatives in the national procurement process as this is essential in order improve overall treatment quality as well as assisting healthcare systems toward achieving sustainability in the future.

We are proud to endorse the PARTNERS programme and wish the European Haemophilia Consortium (EHC), your national patient organisations and most importantly the patients you represent every success for the future of the programme.

Yours sincerely,

Yann Le Cam  
Chief Executive Officer  
EURORDIS – Rare Diseases Europe

